NEW YORK, March 23, 2017 /PRNewswire/ --
A research report by Mordor Intelligence indicates that the global sample preparation market is expected to reach USD 7.2 billion by the end of 2021 and growing at a CAGR of 7.1%. Sample preparation is a procedure in which a sample is preserved prior to its analysis. Preparation is a crucial step in most analytical procedures since the methods are often allowing repeated testing. The report explains that the sample preparation is one of the most shared procedures in the lab. In many life science labs, it can devour most of the lab's capacity, and often encompasses a number of physical error-prone steps. Pressure BioSciences, Inc. (OTC: PBIO), Danaher Corporation (NYSE: DHR), Hologic, Inc. (NASDAQ: HOLX), Koninklijke Philips NV (NYSE: PHG), Illumina, Inc. (NASDAQ: ILMN)
The sample preparation market is segment of the medical devices market. Grace Market Data projects that the global medical devices (MD) market will see a steady growth over the coming years with the sales revenue and international trade value reaching $543.9 billion and $289.2 billion respectively by 2020, which is driven by the aging population, increasing healthcare expenditure and technology advancement. Medical devices are the equipment, instruments used in medical industries by professional surgeons, medical assistants and doctors for healthcare of patients. Companies in this industry manufacture medical devices, surgical equipment and appliances.
Pressure BioSciences, Inc. (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. The products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide.
Just yesterday Pressure BioSciences announced financial results for the fourth quarter and fiscal year ended December 31, 2016. The company stated, "55% Growth in Q4 2016 Products & Services Revenue, Including 70% Increase in Sale of Consumable Supplies, Helps Company Achieve 27% Growth in Products & Services Revenue for Fiscal Year 2016. New Product Releases and Expansion of Sales & Marketing Capabilities Expected to Augment Revenue in FY2017."
Richard T. Schumacher, President and CEO of PBI, commented: "Our accomplishments over the past year have set the stage for what we believe will be a very successful 2017. These accomplishments have let us enter the new year with a stronger balance sheet; a broader product offering; an award-winning, next generation instrument; important additions to our hard-working and talented staff; a larger customer base; and an expanded and enhanced sales and marketing capability."
Mr. Schumacher continued: "Our near-term goals are clear, focused, and attainable in 2017. We believe their achievement will subsequently position PBI to be a stronger, more valuable company. These goals include: (i) an up-list to the NASDAQ stock market in Q2 2017, (ii) measureable progress in completing and implementing a sound roadmap toward financial self-sufficiency and future growth and prosperity, (iii) continuation of the current expansion of our sales and marketing capabilities, and our reach into new countries, investigators, and fields-of-use; and (iv) a focus on sales, sales, and sales."
Danaher Corporation (NYSE: DHR) designs, manufactures and markets professional, medical, industrial and commercial products and services. With more than 20 operating companies, Danaher's globally diverse team of over 62,000 associates is united by a common culture and operating system, the Danaher Business System. Pressure BioSciences, previously announced an exclusive co-marketing agreement with SCIEX, a company focuses on science analytical technologies, and a wholly-owned subsidiary of Danaher Corporation. Under the agreement, the companies will jointly promote Pressure BioSciences' PCT-based sample preparation systems and SCIEX's mass spectrometry equipment, with a focus on improved sample preparation.
Hologic, Inc. (NASDAQ: HOLX) is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. The company recently announced that it has completed the acquisition of Cynosure, Inc., a leader in medical aesthetics systems and technologies.
Koninklijke Philips NV (NYSE: PHG) is a health technology company. The Company's segments include Personal Health businesses, Diagnosis & Treatment businesses, Connected Care & Health Informatics businesses, and Lighting. The Company's Personal Health businesses segment is engaged in the health continuum, delivering integrated, connected solutions that support healthier lifestyles and those living with chronic disease. Recently Philips that the results from two large clinical trials comparing patient outcomes using instant wave-free ratio (iFR) and fractional flow reserve (FFR) in the diagnosis and treatment of heart disease have been published in the New England Journal of Medicine. First released in 2013, iFR is an innovative pressure-derived index unique to Philips, a global leader in image-guided therapy solutions, allowing hyperemia-free physiological assessment of coronary blockages.
Illumina, Inc. (NASDAQ: ILMN) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). On March 21st it was announced that Kailos Genetics, a personalized medicine company offering a leading-edge suite of tools for next-generation sequencing (NGS)-based assays, today announced it has entered into a co-marketing agreement with Illumina, Inc. Under the terms of the agreement, Illumina will market and promote the Kailos TargetRich™ line of research solutions for pharmacogenetics targets through its commercial channels.
Please Sign Up Now at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
For further information: